Terms: = Cervical cancer AND RBM15, Q96T37, 64783, ENSG00000162775, OTT, OTT1 AND Clinical Outcome
4 results:
1. Early outcomes of abbreviated multi-fractionated brachytherapy schedule for cervix cancer during COVID-19 pandemic.
Chopra S; Mulani J; Mittal P; Singh M; Shinde A; Gurram L; Scaria L; Aravindakshan D; Kohle S; Rane P; Ghadi Y; Rath S; Ghosh J; Gulia S; Gupta S; Kinhikar R; Laskar S; Agarwal JP
Brachytherapy; 2023; 22(2):125-131. PubMed ID: 36585283
[TBL] [Abstract] [Full Text] [Related]
2. The tolerance to chemoradiation for cervical cancer patients: A comparative prospective study of rural versus urban population.
Somashekar MK; Gururajachar JM; Arul Ponni TR; Koushik KA; Alva RC
J Cancer Res Ther; 2022; 18(6):1513-1517. PubMed ID: 36412402
[TBL] [Abstract] [Full Text] [Related]
3. Interdigitated versus sequential high-dose-rate intracavitary brachytherapy with external beam radiotherapy in locally advanced carcinoma cervix.
Alam N; Akram M; Siddiqui SA; Hussain MAB
J Cancer Res Ther; 2019; 15(6):1254-1259. PubMed ID: 31898656
[TBL] [Abstract] [Full Text] [Related]
4. Tumour proliferation and apoptosis in human uterine cervix carcinoma II: correlations with clinical outcome.
Tsang RW; Wong CS; Fyles AW; Levin W; Manchul LA; Milosevic M; Chapman W; Li YQ; Pintilie M
Radiother Oncol; 1999 Jan; 50(1):93-101. PubMed ID: 10225562
[TBL] [Abstract] [Full Text] [Related]
